Clinical Trial Update: OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for Tarceva (erlotinib) plus gemcitabine in locally advanced/unresectable or metastatic pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Tarceva (erlotinib)

Snippet

Sponsor: OSI Pharmaceuticals | Conditions: Pancreatic Cancer | Phase 3 | Status: COMPLETED